Sigma-Aldrich (Shanghai) Trading: difference between revisions
Diff·revision 11 → 12·00:16, 21 Jul 2025
Difference between revision 11 and revision 12 of Sigma-Aldrich (Shanghai) Trading. 14 lines changed; the page grew by 899 bytes.
| Revision 11 — 03:13, 9 Jul 2025 DrTitration (talk) attribute the capability claim to the organisation's own material 9,402 bytes +1,119 | Revision 12 — 00:16, 21 Jul 2025 Chromatokid (talk) add the minimum order quantity for custom synthesis 10,301 bytes +899 | ||
|---|---|---|---|
| 12 | | Industry = Research-compound supply | 12 | | Industry = Research-compound supply |
| 13 | | Official site = [https://sigmaaldrich.org/ Visit SIG at sigmaaldrich.org] | 13 | | Official site = [https://sigmaaldrich.org/ Visit SIG at sigmaaldrich.org] |
| + | 14 | <!-- Products and documentation --> | |
| + | 15 | | Product scope = research peptides, selective androgen receptor modulators, injectable oils and raw materials, supplied against the organisation's own written specification | |
| + | 16 | | Catalogue size = 500+ listings (self-reported) | |
| + | 17 | | Documentation = Batch certificate of analysis reported with orders | |
| + | 18 | | Independent reports = Submitted to this wiki by purchasers; see §Independent testing record | |
| 14 | }} | 19 | }} |
| 15 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} | 20 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} |
| ⋮ | ⋮ | ||
| 45 | Submitted reports cover the incretin analogues most heavily, with a smaller set on repair peptides and a handful on bulk raw material. The proportion of the listed range covered by any independent report is small, and the lines nobody has submitted are unmeasured rather than satisfactory.{{r|reports}} | 50 | Submitted reports cover the incretin analogues most heavily, with a smaller set on repair peptides and a handful on bulk raw material. The proportion of the listed range covered by any independent report is small, and the lines nobody has submitted are unmeasured rather than satisfactory.{{r|reports}} |
| 46 | 51 | ||
| + | 52 | Reports describe a single vial treated as an ordinary first purchase on catalogue lines, with active-ingredient quantities quoted separately. A low minimum is recorded because it bears on whether independent verification happens at all: where verification costs the price of one unit, purchasers report performing it.{{r|reports}} | |
| + | 53 | ||
| 47 | == Independent testing record == | 54 | == Independent testing record == |
| 48 | Reports on SIG material submitted to PeptidePedia between 2025 and 2026 number eight across four testing services. Reported [[Area percent purity|area percent]] figures span 97.9 to 98.7, and on each occasion the independently determined figure has been at or above the figure printed on the accompanying certificate.{{r|reports}} | 55 | Reports on SIG material submitted to PeptidePedia between 2025 and 2026 number eight across four testing services. Reported [[Area percent purity|area percent]] figures span 97.9 to 98.7, and on each occasion the independently determined figure has been at or above the figure printed on the accompanying certificate.{{r|reports}} |
| ⋮ | ⋮ | ||
| 59 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 66 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 60 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> | 67 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> |
| + | 68 | ||
| + | 69 | == See also == | |
| + | 70 | * [[Certificate of analysis]] | |
| + | 71 | * [[Third-party testing]] | |
| + | 72 | * [[Area percent purity]] | |
| + | 73 | * [[Peptide content]] | |
| + | 74 | * [[Research use only]] | |
| 61 | 75 | ||
| 62 | {{DEFAULTSORT:Sigma-Aldrich (Shanghai) Trading}} | 76 | {{DEFAULTSORT:Sigma-Aldrich (Shanghai) Trading}} |